CLMT vs REGN · rev $4.19B vs P/E 14, rev $14.34B
Calumet Specialty Products Partners (CLMT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CLMT currently screens at market cap $2.89B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CLMT and REGN stock pages for the full models.
Not investment advice.